Literature DB >> 25195512

Costimulatory molecules as vaccine adjuvants: to 4-1BB or not to 4-1BB?

Khalidur Rahman1, Smita S Iyer2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25195512      PMCID： PMC4496544          DOI： 10.1038/cmi.2014.90

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN： 1672-7681            Impact factor:   11.530


× No keyword cloud information.
  9 in total

1.  4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy.

Authors:  Hua Zhang; Kristen M Snyder; Megan M Suhoski; Marcela V Maus; Veena Kapoor; Carl H June; Crystal L Mackall
Journal:  J Immunol       Date:  2007-10-01       Impact factor: 5.422

Review 2.  Key roles of adjuvants in modern vaccines.

Authors:  Steven G Reed; Mark T Orr; Christopher B Fox
Journal:  Nat Med       Date:  2013-12-05       Impact factor: 53.440

Review 3.  TNF/TNFR family members in costimulation of T cell responses.

Authors:  Tania H Watts
Journal:  Annu Rev Immunol       Date:  2005       Impact factor: 28.527

4.  4-1BB signaling synergizes with programmed death ligand 1 blockade to augment CD8 T cell responses during chronic viral infection.

Authors:  Vaiva Vezys; Pablo Penaloza-MacMaster; Daniel L Barber; Sang-Jun Ha; Bogumila Konieczny; Gordon J Freeman; Robert S Mittler; Rafi Ahmed
Journal:  J Immunol       Date:  2011-07-08       Impact factor: 5.422

5.  Targeting 4-1BB costimulation to disseminated tumor lesions with bi-specific oligonucleotide aptamers.

Authors:  Fernando Pastor; Despina Kolonias; James O McNamara; Eli Gilboa
Journal:  Mol Ther       Date:  2011-08-09       Impact factor: 11.454

6.  Adjuvantive effects of anti-4-1BB agonist Ab and 4-1BBL DNA for a HIV-1 Gag DNA vaccine: different effects on cellular and humoral immunity.

Authors:  Sumita Ganguly; Jinyan Liu; Vinod B Pillai; Robert S Mittler; Rama Rao Amara
Journal:  Vaccine       Date:  2009-11-26       Impact factor: 3.641

7.  Costimulatory ligand 4-1BBL (CD137L) as an efficient adjuvant for human antiviral cytotoxic T cell responses.

Authors:  Jacob Bukczynski; Tao Wen; Kim Ellefsen; Jack Gauldie; Tania H Watts
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-26       Impact factor: 11.205

8.  Transgenic 4-1BBL-engineered vaccine stimulates potent Gag-specific therapeutic and long-term immunity via increased priming of CD44(+)CD62L(high) IL-7R(+) CTLs with up- and downregulation of anti- and pro-apoptosis genes.

Authors:  Rong Wang; Andrew Freywald; Yue Chen; Jianqing Xu; Xin Tan; Jim Xiang
Journal:  Cell Mol Immunol       Date:  2014-09-08       Impact factor: 11.530

9.  Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin.

Authors:  Michael A Curran; Theresa L Geiger; Welby Montalvo; Myoungjoo Kim; Steven L Reiner; Aymen Al-Shamkhani; Joseph C Sun; James P Allison
Journal:  J Exp Med       Date:  2013-04-01       Impact factor: 14.307
  9 in total
  2 in total

1.  Agonist-induced 4-1BB activation prevents the development of Sjӧgren's syndrome-like sialadenitis in non-obese diabetic mice.

Authors:  Jing Zhou; Bo Ra You; Qing Yu
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2019-11-15       Impact factor: 5.187

Review 2.  Chimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy.

Authors:  Yuan Hu; Zhi-Gang Tian; Cai Zhang
Journal:  Acta Pharmacol Sin       Date:  2017-09-07       Impact factor: 6.150
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.